[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387851":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":28,"responsibleParty":146,"collaborators":148,"id":154,"slug":155,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":162,"sex":163,"minAge":164,"maxAge":10,"enrollmentInfo":165,"targetDuration":10,"studyType":168,"phases":10,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8,11,14,16],{"label":9,"type":10,"description":10,"interventionNames":10},"20 patients with DRESS syndrome",null,{"label":12,"type":10,"description":13,"interventionNames":10},"20 patients with drug induced MPE with eosinophilia","patients with drug induced maculopapular exanthema (MPE) with eosinophilia",{"label":15,"type":10,"description":10,"interventionNames":10},"20 patients with drug induced MPE without eosinophilia",{"label":17,"type":10,"description":10,"interventionNames":10},"20 Healthy subjects",[19],{"name":20,"affiliation":5,"role":21},"Delphine Staumont-Salle, MD,PhD","PRINCIPAL_INVESTIGATOR",[23],{"name":20,"role":24,"phone":25,"phoneExt":26,"email":27},"CONTACT","0320444193","+33","delphine.salle@chru-lille.fr",[29,44,55,66,77,88,96,105,113,124,135],{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"CH d'Arras","RECRUITING","Arras","France","FR",{"type":36,"coordinates":37},"Point",[38,39],2.78186,50.29301,{"lat":39,"lon":38},[42],{"name":43,"role":21,"phone":10,"phoneExt":10,"email":10},"Céline DESVIGNES",{"facility":45,"status":31,"city":46,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"CH de Boulogne","Boulogne-sur-Mer",{"type":36,"coordinates":48},[49,50],1.61373,50.72485,{"lat":50,"lon":49},[53],{"name":54,"role":21,"phone":10,"phoneExt":10,"email":10},"Sophie DARRAS",{"facility":56,"status":31,"city":57,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Assistance Publique - Hôpitaux de Paris - HENRI MONDOR","Créteil",{"type":36,"coordinates":59},[60,61],2.46569,48.79266,{"lat":61,"lon":60},[64],{"name":65,"role":21,"phone":10,"phoneExt":10,"email":10},"Olivier Chosidow",{"facility":67,"status":31,"city":68,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"CH de Douai","Douai",{"type":36,"coordinates":70},[71,72],3.07922,50.37069,{"lat":72,"lon":71},[75],{"name":76,"role":21,"phone":10,"phoneExt":10,"email":10},"Eve DESMEDT",{"facility":78,"status":31,"city":79,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CH de Dunkerque","Dunkirk",{"type":36,"coordinates":81},[82,83],2.37681,51.0344,{"lat":83,"lon":82},[86],{"name":87,"role":21,"phone":10,"phoneExt":10,"email":10},"SOPHIE DUVERT-LEHEMBRE",{"facility":89,"status":31,"city":90,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":91,"geoPoint":95,"contacts":10},"CH LENS","Lens",{"type":36,"coordinates":92},[93,94],2.82791,50.43302,{"lat":94,"lon":93},{"facility":97,"status":31,"city":98,"state":10,"zip":99,"country":33,"countryCode":34,"cosmosGeoPoint":100,"geoPoint":104,"contacts":10},"Hop Claude Huriez Chr Lille","Lille","59000",{"type":36,"coordinates":101},[102,103],3.05512,50.63391,{"lat":103,"lon":102},{"facility":106,"status":31,"city":98,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":107,"geoPoint":109,"contacts":110},"Groupe Hospitalier de l'Institut Catholique de Lille",{"type":36,"coordinates":108},[102,103],{"lat":103,"lon":102},[111],{"name":112,"role":21,"phone":10,"phoneExt":10,"email":10},"PHILIPPE MODIANO",{"facility":114,"status":31,"city":115,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"CH de Roubaix","Roubaix",{"type":36,"coordinates":117},[118,119],3.17456,50.69421,{"lat":119,"lon":118},[122],{"name":123,"role":21,"phone":10,"phoneExt":10,"email":10},"Olivier CARPENTIER",{"facility":125,"status":31,"city":126,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Hôpital FOCH","Suresnes",{"type":36,"coordinates":128},[129,130],2.22929,48.87143,{"lat":130,"lon":129},[133],{"name":134,"role":21,"phone":10,"phoneExt":10,"email":10},"Matthieu GROH",{"facility":136,"status":31,"city":137,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"CH de Valenciennes","Valenciennes",{"type":36,"coordinates":139},[140,141],3.52506,50.35909,{"lat":141,"lon":140},[144],{"name":145,"role":21,"phone":10,"phoneExt":10,"email":10},"Marie WEINBORN",{"type":147,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[149,151],{"name":150,"class":6},"Société de Dermatologie Française",{"name":152,"class":153},"Société de Recherche en Dermatologie","UNKNOWN","100387851","origin-and-function-of-eosinophilic-polynuclear-during-dress-syndrome-100387851",false,"NCT04330118","Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome","Origin and Function of Eosinophilic Polynuclear During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome","DRESSEO","Inclusion Criteria:\n\nGroup 1 (DRESS): adult with a diagnosis of DRESS based on the following four criteria:\n\n* Cutaneous rash occurring at least 24 hours and at most 2 months after continuous medication use\n* Fever over 38 degre celcius\n* At least one organ dysfunction among:\n* Lymphadenopathy\n* hepatitis\n* Pulmonary involvement\n* Cardiac involvement: myocarditis, pericarditis\n* Renal impairment\n* At least one of the following hematological anomalies:\n* Eosinophilia ≥ 500 \u002F mm3 .\n* RegiSCAR Score ≥ 4\n\nGroups 2 and 3 (Drug induced maculopapular exanthema without or with eosinophilia).\n\n* Adult with drug-induced rash\n* Without clinical criteria of severity defined by Djien among :\n* An evolution of more than 21 days\n* with organ damage as defined in group 1\n\nGroup 2 (MPE without eosinophilia): blood eosinophils \\\u003C 500 \u002F mm3\n\nGroup 3 (MPE with eosinophilia): blood eosinophils ≥ 500 \u002F mm3\n\nExclusion Criteria:\n\n* Other cause of eosinophilia including cancer, blood disease before the introduction of suspected molecule(s).\n* On going oral or local corticosteroid therapy, anti-leukotriene therapy (MONTELUKAST) by the month preceding the study;\n* Anti-IgE therapy (OMALIZUMAB, LIGELIZUMAB), anti-IL-5 therapy (MEPOLIZUMAB, BENRALIZUMAB) or anti-IL4 and \u002F or anti-IL13 therapy (DUPILUMAB, TRALOKINUMAB) in the 6 months preceding the study.\n* Any pregnant or lactating woman.\n* Contraindication related to the blood volume taken for the study.",true,"ALL","18 Years",{"count":166,"type":167},80,"ESTIMATED","OBSERVATIONAL","Drug Hypersensitivity Syndrome or DRESS for \"Drug Reaction with Eosinophilia and Systemic Symptoms\" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.",[171,172],"Drug Hypersensitivity","DRESS Syndrome",[174,175,176,177],"DRESS syndrome","Drug hypersensitivity","eosinophils","allergy","2026-04-21",{"date":180,"type":181},"2026-04-22","ACTUAL",{"date":183,"type":181},"2020-07-15",{"date":185,"type":167},"2027-10",{"name":5,"class":6},11]